We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

How to try and turn a small ISA into £100k using these S&P 500 stocks

Jon Smith turns his focus to building a portfolio solely with S&P 500 stocks, and taps into key growth areas he sees for the next decade.

| More on:
Diverse children studying outdoors

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

S&P 500 stocks offer UK investors a way to diversify their exposure away from the domestic stock market. Given the breadth of companies in the index, and the returns from the past few years, some might consider trying to build a portfolio solely around US stocks. In that case, here’s how I’d go about it.

Building the ISA

The first point I’d note is that the investor could do well to house the portfolio within an ISA. This means the investor can benefit from certain tax advantages, with most major brokers allowing UK investors to hold US stocks.

XXX

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

There’s a £20k cap on the amount that can be invested in an ISA each year. I’m going to assume that someone has £5k in an ISA right now and can afford to add an additional £500 a month, aiming for it to reach £100k in value.

Next, we turn to portfolio allocation. The US is home to most of the major tech and artificial intelligence (AI) companies. Particularly when I look at AI, I think it’s a theme that will keep playing out for years to come.

As a result, I think a good portion of the ISA should be allocated to firms from this sector. For the remainder, I’d look to build a diversified portfolio with a focus on healthcare and consumer staples. These more mature areas of the market should help to reduce the risk associated with some high-growth tech stocks.

Reaching six figures

In terms of numbers, I think it’s fair to target a 10% annual return on the portfolio. Interestingly, over the past decade, the S&P 500’s risen by 366%. So I feel my future estimate’s conservative. Obviously, predicting years in advance isn’t an exact science at all!

Using this assumption, the portfolio could grow to £100k by the beginning of year 10. From that point onwards, the investor could decide not to add funds and just let the pot compound.

The risk is that during this period, we see a sustained stock market correction, which could throw the estimates off and delay reaching the goal.

US shares to analyse

In terms of specific stocks, tech companies like Alphabet and Meta could be considered. I feel they are large enough, with different fingers in various pies, to be able to pivot to whatever part of the AI ecosystem turns out to be the most profitable.

Aside from those stocks, another to consider is Johnson & Johnson (NYSE:JNJ). The share price is up 49% in the past year. At 2.32%, the dividend yield might not be super high, but it has been increased it for over 50 consecutive years.

Fundamentally, I think it’s a healthcare stock that’s well-positioned for the shift as the US population grows older. Further, it’s diversified, given it operates divisions including pharmaceuticals, medical devices, and even MedTech. This gives it a balanced mix of growth and defensive stability, which I think is valuable to have in the ISA alongside tech stocks.

In terms of risks, patent expiries on key products can be a headache. For example, Stelara, a previously high-revenue treatment, has seen sharp declines in sales as exclusivity deals roll off. Yet even with this concern, I still feel it’s a solid US stock worthy of further research.

Jon Smith has no position in any of the shares mentioned. The Motley Fool UK has recommended Alphabet and Meta Platforms. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on US Stock

Transparent umbrella under heavy rain against water drops splash background.
Investing Articles

I’m following Warren Buffett’s advice for when stocks are at record highs

Stocks are near all-time highs, and nerves are rising. Here's what Warren Buffett recommends doing, and the quality stock that…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£20k invested in a Stocks and Shares ISA this time last year is now worth…

What has 12 months meant for the value of a Stocks and Shares ISA? That depends on how it has…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

While everyone’s piling into AI infrastructure stocks like Micron and SanDisk, consider these out-of-favour Nasdaq 100 names

There’s very little interest in these Nasdaq-listed AI stocks right now despite the fact they’re generating impressive growth. Could this…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

This S&P 500 stock continues to underperform in my ISA. What’s my next move?

Stephen Wright looks at the struggles of an underperforming S&P 500 stock. Should he cut his losses and move on,…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Could buying Microsoft stock now be like buying Alphabet in mid-2025 at a share price of $150?

Microsoft’s share price has fallen in 2026 as investors moved away from software names. But Edward Sheldon sees potential for…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Should I dump Duolingo from my ISA and buy Palantir stock instead?

These two AI-powered software stocks have been heading in very different directions, making me wonder if I should sell one…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett just sounded an alarm to the stock market

Last week Warren Buffett used a six-letter word that should give investors pause for thought. But is the Oracle of…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Palantir stock: I’m buying the dip after this week’s blowout Q1 earnings

AI stock Palantir experienced some weakness after its Q1 earnings, despite the fact that revenue climbed an incredible 85% year…

Read more »